(ICU)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
| Name | Position |
|---|---|
| Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
| Dr. H. David Humes M.D. | Co-Founder & Scientific Advisor |
| Mr. Bradford K. Towne CPA | Principal Accounting Officer |
| Mr. Eric Schlorff | CEO, Treasurer, President & Executive Director |
| Mr. Michael Messinger CPA | Chief Financial Officer |
| Mr. Sai P. Iyer Ph.D. | Senior Vice President of Medical Affairs & Research |
| Mr. Tim Varacek | Senior Vice President of Commercial & Business Operations |
| Date | Type | Document |
|---|---|---|
| 2026-01-20 | 8-K | icu20260117_8k.htm |
| 2025-12-23 | 8-K/A | icu20251223_8ka.htm |
| 2025-12-18 | 8-K | icu20251217_8k.htm |
| 2025-11-17 | 8-K | icu20251111c_8k.htm |
| 2025-11-14 | DEF 14A | ea0263820-02.htm |
| 2025-11-13 | 10-Q | icu20250930_10q.htm |
| 2025-11-04 | PRE 14A | ea0263820-01.htm |
| 2025-09-29 | 8-K | icu20250928_8k.htm |
| 2025-09-24 | 8-K | icu-20250924.htm |
| 2025-08-19 | 8-K | icu-20250813.htm |
| Mr. Tom Mullen |
| Vice President of Operations & Product Development |